Full Press Release Details
Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
to feature principal investigators from the trial
ANGELES - September 11, 2025 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company
focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at
5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead
candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested
participants can sign-up to receive the webcast link here.
safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy results in treating
prostate cancer patients. This predetermined efficacy analysis occurs four months after start of combination therapy of ENV105 and apalutamide
in the last safety lead-in patient. We hope to lay out the primary benefits of our compound, and to clearly demonstrate the clinical
need filled by ENV105," said Dr. John Yu, CEO of Kairos Pharma. "This distinguished panel of experts will provide participants
with a renewed understanding of the importance of these data and the role ENV105 can have in targeting cancer drug resistance."
in the KOL event include Dr. Neil Bhowmick, President and Chief Scientific Officer at Kairos Pharma; Dr. Umang Swami, Associate Professor
in the Division of Oncology, Department of Internal Medicine at the Huntsman Cancer Institute; Dr. Richard Lee, Clinical Co-Director,
The Claire and John Bertucci Center for Genitourinary Cancers at Massachusetts General Hospital, Harvard Medical School, and Dr. Edwin
Posadas, Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence
at the Samuel Oschin Comprehensive Cancer Institute.
interim safety analysis of the trial, announced in July of this year, demonstrated that ENV105, a first-in-class CD105 antagonist, was
well tolerated when combined with standard of care hormone therapy, apalutamide, from the first 10 enrolled patients. Thus far, there
have been no dose-limiting toxicities or unexpected adverse events reported to date. In addition, the treatment-related side effects
were manageable with standard supportive care. Notably, no Grade 3 or 4 toxicities were observed.
one million men in the US diagnosed with prostate cancer each year, and millions more worldwide, the development of resistance to current
hormone therapies is a growing unmet need with an increasingly aging population. Castration-resistant prostate cancer refers to tumors
that grow despite receiving hormone blocking agents. Treatment options remain limited after hormone therapies fail. Kairos Pharma seeks
to provide a safe and effective alternative for these patients with ENV-105.
in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) aims to work at the forefront of oncology therapeutics, utilizing
structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets
CD105 - a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard
therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness
of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate
cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You
can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates," "believes,"
"plans," "projected," "predicts," "potential" or "hopes" or the negative
of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate,
or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from
the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating
these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion
of our Phase 2 clinical trial; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory
approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the
uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking
statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other
statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and
are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's Annual Report on Form
10-K, as amended, and our other filings made with the Securities and Exchange Commission. We are not obligated to publicly update or
revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information
or future events or developments, except as required by U.S. federal securities laws.